旨在评估挽救性立体定向消融体部放疗 (SABR) 治疗热消融 (TA) 后复发性肾细胞癌 (RCC) 的有效性和安全性。本研究是一项多机构回顾性分析，对 TA 后接受 SABR 的患者进行了多机构回顾性分析。 2016 年和 2020 年。主要研究结果是无局部失败，根据实体瘤疗效评估标准 (RECIST) v1.1 进行放射学评估。 SABR 后的远处衰竭、癌症特异性生存 (CSS)、总生存 (OS)、治疗相关毒性和肾功能变化是次要结果。 Kaplan-Meier 方法用于估计无局部和远处失败、CSS 和 OS。纳入了 17 名患有 18 个活检确诊 RCC 的患者，SABR 时的中位年龄（四分位距 [IQR]）为 75.2 (72.6) -68.7）年，中位（IQR）肿瘤大小为3.5 （1.9-4.1）厘米，随访（反向Kaplan-Meier方法）为3.36 （95％置信区间[CI] 1.6-4.1）年。 17 名患者中有 6 名有孤立肾。 5 名患者在 SABR 之前重复 TA 失败。从 TA 手术到 SABR 的中位时间 (IQR) 为 3.03 (1.5-5.1) 年。无患者出现局部进展，局部控制率为100%。四名患者（其中两名患有基线转移性疾病）经历了远处进展。 3 年时的远处无进展生存率、CSS 和 OS 分别为 72.1% (95% CI 51.9%-100%)、92.3% (95% CI 78.9%-100%) 和 82.1% (95% CI 62.1%-100) ％）， 分别。 SABR前的中位肾小球滤过率（IQR）为58（40-71）mL/min，末次随访时为48（33-57）mL/min。没有患者经历 3 级毒性或继续发展为终末期肾病。结果表明，对于 TA 后复发性 RCC 患者，SABR 似乎是一种有效且安全的挽救策略。© 2024 BJU International。

To evaluate the effectiveness and safety of salvage stereotactic ablative body radiotherapy (SABR) for recurrent renal cell carcinoma (RCC) after thermal ablation (TA).This study was a multi-institutional retrospective analysis of patients with recurrent RCC following TA who received SABR between 2016 and 2020. The primary study outcome was freedom from local failure, evaluated radiographically based on Response Evaluation Criteria in Solid Tumours (RECIST) v1.1. Distant failure, cancer-specific survival (CSS), overall survival (OS), treatment-related toxicity and renal function changes following SABR were the secondary outcomes. The Kaplan-Meier method was used to estimate freedom from local and distant failure, CSS and OS.Seventeen patients with 18 biopsy-confirmed RCCs were included, with a median (interquartile range [IQR]) age at time of SABR of 75.2 (72.6-68.7) years, a median (IQR) tumour size of 3.5 (1.9-4.1) cm and follow-up (reverse Kaplan-Meier method) of 3.36 (95% confidence interval [CI] 1.6-4.1) years. Six of the 17 patients had a solitary kidney. Five patients had failed repeat TA prior to SABR. The median (IQR) time from TA procedure to SABR was 3.03 (1.5-5.1) years. No patient experienced local progression, with a local control rate of 100%. Four patients, two with baseline metastatic disease, experienced distant progression. The distant progression-free survival, CSS and OS at 3 years were 72.1% (95% CI 51.9%-100%), 92.3% (95% CI 78.9%-100%) and 82.1% (95% CI 62.1%-100%), respectively. The median (IQR) glomerular filtration rate before SABR was 58 (40-71) mL/min, and at last follow-up, it was 48 (33-57) mL/min. No patient experienced grade 3+ toxicity or went on to develop end-stage renal disease.The results showed that SABR appears to be an effective and safe salvage strategy in patients with recurrent RCC following TA.© 2024 BJU International.